» Articles » PMID: 35327663

Structural Comparative Modeling of Multi-Domain F508del CFTR

Overview
Journal Biomolecules
Publisher MDPI
Date 2022 Mar 25
PMID 35327663
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is a rare genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), an epithelial anion channel expressed in several vital organs. Absence of functional CFTR results in imbalanced osmotic equilibrium and subsequent mucus build up in the lungs-which increases the risk of infection and eventually causes death. CFTR is an ATP-binding cassette (ABC) transporter family protein composed of two transmembrane domains (TMDs), two nucleotide binding domains (NBDs), and an unstructured regulatory domain. The most prevalent patient mutation is the deletion of F508 (F508del), making F508del CFTR the primary target for current FDA approved CF therapies. However, no experimental multi-domain F508del CFTR structure has been determined and few studies have modeled F508del using multi-domain WT CFTR structures. Here, we used cryo-EM density data and Rosetta comparative modeling (RosettaCM) to compare a F508del model with published experimental data on CFTR NBD1 thermodynamics. We then apply this modeling method to generate multi-domain WT and F508del CFTR structural models. These models demonstrate the destabilizing effects of F508del on NBD1 and the NBD1/TMD interface in both the inactive and active conformation of CFTR. Furthermore, we modeled F508del/R1070W and F508del bound to the CFTR corrector VX-809. Our models reveal the stabilizing effects of VX-809 on multi-domain models of F508del CFTR and pave the way for rational design of additional drugs that target F508del CFTR for treatment of CF.

Citing Articles

ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches.

Elbahnsi A, Dudas B, Callebaut I, Hinzpeter A, Miteva M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770445 PMC: 11676857. DOI: 10.3390/ph17121602.


Identification of novel natural compounds against CFTR p.Gly628Arg pathogenic variant.

Khan M, Sakhawat A, Rehman R, Wali A, Ghani M, Akram A AMB Express. 2024; 14(1):99.

PMID: 39249658 PMC: 11383896. DOI: 10.1186/s13568-024-01762-9.


Proteostasis Landscapes of Cystic Fibrosis Variants Reveals Drug Response Vulnerability.

McDonald E, Kim M, Olson 3rd J, Olson J, Meiler J, Plate L bioRxiv. 2024; .

PMID: 39026768 PMC: 11257600. DOI: 10.1101/2024.07.10.602964.


Benchmarking AlphaMissense pathogenicity predictions against cystic fibrosis variants.

McDonald E, Oliver K, Schlebach J, Meiler J, Plate L PLoS One. 2024; 19(1):e0297560.

PMID: 38271453 PMC: 10810519. DOI: 10.1371/journal.pone.0297560.


Dark nanodiscs for evaluating membrane protein thermostability by differential scanning fluorimetry.

Selvasingh J, McDonald E, Neufer P, McKinney J, Meiler J, Ledwitch K Biophys J. 2023; 123(1):68-79.

PMID: 37978799 PMC: 10808023. DOI: 10.1016/j.bpj.2023.11.019.


References
1.
Liu F, Zhang Z, Csanady L, Gadsby D, Chen J . Molecular Structure of the Human CFTR Ion Channel. Cell. 2017; 169(1):85-95.e8. DOI: 10.1016/j.cell.2017.02.024. View

2.
Brown B, Mendenhall J, Geanes A, Meiler J . General Purpose Structure-Based Drug Discovery Neural Network Score Functions with Human-Interpretable Pharmacophore Maps. J Chem Inf Model. 2021; 61(2):603-620. PMC: 7903419. DOI: 10.1021/acs.jcim.0c01001. View

3.
Lopes-Pacheco M, Silva I, Turner M, Carlile G, Sondo E, Thomas D . Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR. Biochem Pharmacol. 2020; 180:114133. DOI: 10.1016/j.bcp.2020.114133. View

4.
Estacio S, Martiniano H, Faisca P . Thermal unfolding simulations of NBD1 domain variants reveal structural motifs associated with the impaired folding of F508del-CFTR. Mol Biosyst. 2016; 12(9):2834-48. DOI: 10.1039/c6mb00193a. View

5.
Loo T, Bartlett M, Clarke D . Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Biochem Pharmacol. 2013; 86(5):612-9. DOI: 10.1016/j.bcp.2013.06.028. View